niacinamide has been researched along with Leiomyosarcoma in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Leiomyosarcoma: A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib appears to be a promising option in leiomyosarcoma patients." | 9.17 | Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. ( Basso, U; Bertuzzi, A; Boglione, A; Comandone, A; De Sanctis, R; Giordano, L; Lutman, FR; Marcon, I; Santoro, A; Soto Parra, H; Stroppa, E, 2013) |
| "The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease." | 9.16 | Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. ( Borden, E; Bramwell, V; Demetri, GD; Goldblum, JR; Rankin, C; Ryan, CW; von Mehren, M, 2012) |
| "Sorafenib appears to be a promising option in leiomyosarcoma patients." | 5.17 | Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. ( Basso, U; Bertuzzi, A; Boglione, A; Comandone, A; De Sanctis, R; Giordano, L; Lutman, FR; Marcon, I; Santoro, A; Soto Parra, H; Stroppa, E, 2013) |
| "The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease." | 5.16 | Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. ( Borden, E; Bramwell, V; Demetri, GD; Goldblum, JR; Rankin, C; Ryan, CW; von Mehren, M, 2012) |
| "Fifteen patients presented with metastases at the time of diagnosis." | 1.40 | Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas. ( Bauernhofer, T; Brämswig, K; Brodowicz, T; Girschikofsky, M; Hilbe, W; Hochreiner, G; Kühr, T; Leitgeb, C; Martel, A; Mlineritsch, B; Petzer, A; Ploner, F; Ressler, S; Romeder, F; Seebacher, V; Stöger, H; Wöll, E, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brämswig, K | 1 |
| Ploner, F | 1 |
| Martel, A | 1 |
| Bauernhofer, T | 1 |
| Hilbe, W | 1 |
| Kühr, T | 1 |
| Leitgeb, C | 1 |
| Mlineritsch, B | 1 |
| Petzer, A | 1 |
| Seebacher, V | 1 |
| Stöger, H | 1 |
| Girschikofsky, M | 1 |
| Hochreiner, G | 1 |
| Ressler, S | 1 |
| Romeder, F | 1 |
| Wöll, E | 1 |
| Brodowicz, T | 1 |
| von Mehren, M | 1 |
| Rankin, C | 1 |
| Goldblum, JR | 1 |
| Demetri, GD | 1 |
| Bramwell, V | 1 |
| Ryan, CW | 1 |
| Borden, E | 1 |
| Santoro, A | 1 |
| Comandone, A | 1 |
| Basso, U | 1 |
| Soto Parra, H | 1 |
| De Sanctis, R | 1 |
| Stroppa, E | 1 |
| Marcon, I | 1 |
| Giordano, L | 1 |
| Lutman, FR | 1 |
| Boglione, A | 1 |
| Bertuzzi, A | 1 |
| Kong, HH | 1 |
| Cowen, EW | 1 |
| Azad, NS | 1 |
| Dahut, W | 1 |
| Gutierrez, M | 1 |
| Turner, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer[NCT00090545] | Phase 2 | 46 participants (Actual) | Interventional | 2004-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Geometric mean exposure for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | mg/L.h (Geometric Mean) |
|---|---|
| First Stage - Disease Progression | 9.76 |
| Second Stage - Increased Accrual | 18.63 |
Plasma concentration-time profile for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, AND 24 hours post dose
| Intervention | mg/L (Mean) |
|---|---|
| First Stage - Disease Progression | 1.28 |
| Second Stage - Increased Accrual | 2.57 |
Time from treatment start date until date of death or date last known alive. (NCT00090545)
Timeframe: Time from treatment start date until date of death or date last known alive, approximately 18.3 months.
| Intervention | Months (Median) |
|---|---|
| First Stage - Disease Progression | 18 |
| Second Stage - Increased Accrual | 18.3 |
Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. (NCT00090545)
Timeframe: Date treatment consent signed to date off study, approximately 49 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| First Stage - Disease Progression | 22 |
| Second Stage - Increased Accrual | 23 |
Determine whether BAY 43-9006 when used to treat metastatic prostate cancer is associated with having 50% of Patients Progression Free at 4 Months by clinical, radiographic, and prostatic specific antigen (PSA)criteria. (NCT00090545)
Timeframe: 4 months
| Intervention | months (Median) |
|---|---|
| First Stage - Disease Progression | 1.83 |
| Second Stage - Increased Accrual | 3.7 |
Time to maximum concentration for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | hours (Median) |
|---|---|
| First Stage - Disease Progression | 0.68 |
| Second Stage - Increased Accrual | 8 |
Overall response was evaluated by the RECIST. Complete Response (CR) is the disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00090545)
Timeframe: Every 2 cycles (1 cycle = 28 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| First Stage - Disease Progression | 0 | 0 | 8 | 0 |
| Second Stage - Increased Accrual | 0 | 1 | 13 | 10 |
2 trials available for niacinamide and Leiomyosarcoma
| Article | Year |
|---|---|
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Leiomyosar | 2012 |
Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Disease-Free Survival; Female; Humans; Leiomyosarcom | 2013 |
2 other studies available for niacinamide and Leiomyosarcoma
| Article | Year |
|---|---|
Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leiomyosarcoma; Male; Middle | 2014 |
Keratoacanthomas associated with sorafenib therapy.
Topics: Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Facial Dermatoses; Female; Humans; Keratoacanth | 2007 |